Caribou Biosciences

IPO

Developing Sophisticated Allogeneic Cell Therapies

Public · Berkeley, United States · Founded 2011 · $181.0M raised

Employees
51–200
Founded
2011
Business Model
B2B
Total Funding
$181.0M
Last Round
$25.0M Corporate RoundJul 2023
Rounds
4
Type
Public

Totals include recorded grants and other qualifying funding, not just equity. What counts toward funding.

About

Caribou Biosciences is a clinical-stage CRISPR genome-editing biopharmaceutical company dedicated to developing transformative therapies for patients with devastating diseases. Its proprietary Cas12a chRDNA (CRISPR hybrid RNA-DNA) genome-editing platform enables superior precision for complex multiplex editing, including gene knockout and insertion. Caribou is advancing CB-010 and CB-011 as off-the-shelf allogeneic CAR-T cell therapies targeting hematologic malignancies.

Summary

Caribou Biosciences is a Biotech company based in Berkeley, United States, founded in 2011. It has raised $181.0M in total across 4 rounds, most recently a $25.0M Corporate Round in Jul 2023. Investors include Pfizer Ventures, Fidelity Biosciences and AbbVie Ventures.

Tech & App Stack

3 technologies & apps tracked

Every product and vendor across these categories, with where each signal came from.

Create a free account with 25 free credits every month, no card needed, to unlock the full tech & app stack, funding history, and valuations.

Funding & Exit History

Corporate RoundCorporate RoundJul 2023
$25.0M

Sign up to see all 5 events

Funding: Series A through Corporate Round. Amounts, valuations, and investors where available.

Investors

Similar Companies

Sana BiotechnologyIPO

Developer of engineered cells as medicines to treat diseases by repairing or replacing cells for ...

Seattle, United States201–500Biotech, Healthcare
Series DTotal funding$1.4BJun 2020
Altos Labs

Altos Labs combines academic science and industry development to create medicines that restore ce...

San Francisco, United States501–1000Life Sciences, Biotech
Series ATotal funding$3.0BJan 2022
BridgeBioIPO

BridgeBio develops treatments for genetic conditions through autonomous condition-focused teams s...

San Francisco Bay Area, United States201–500Biotech, Healthcare
Growth EquityTotal funding$2.7BJul 2026
AsymchemIPO

Asymchem is a pharmaceutical CDMO providing R&D, chemistry, manufacturing, and control services t...

Tianjin, China5001–10000Biotech, Drug Discovery
Private EquityTotal funding$2.3BFeb 2020
Calico

Calico researches human aging using advanced technologies and model systems, applying that knowle...

South San Francisco, United States201–500Biotech, Healthcare
Corporate RoundTotal funding$2.3BJun 2018
Paratek PharmaceuticalsAcquired

Paratek Pharmaceuticals develops and delivers innovative treatments for serious infectious diseas...

Boston, United States201–500Biotech, Healthcare
ConvertibleTotal funding$1.8BApr 2018

Your company? Embed this profile

Add the live badge to your site — it stays current as your funding data updates.

Caribou Biosciences on Indexed.vc
<a href="https://indexed.vc/companies/caribou-biosciences"><img src="https://indexed.vc/api/badge/company/caribou-biosciences" alt="Caribou Biosciences on Indexed.vc" width="260" height="76" /></a>